Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Two orphan receptor proteins exert fatal double whammy effect against glioblastoma cells

Two related proteins exert a lethal double whammy effect against glioblastoma cells when activated with a small molecule, say researchers at Georgetown Lombardi Comprehensive Cancer Center. [More]
University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals. [More]
Researchers identify a single protein as root cause of multiple allergic reactions

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV [More]
Scientists produce novel class of molecules that could help combat cancer, other diseases

Scientists produce novel class of molecules that could help combat cancer, other diseases

Promising treatments known as biologics are on the market and under development for many serious illnesses such as cancer, but some of them come with high risks, even lethal ones. Now scientists have produced a novel class of molecules that could be as effective but without the dangerous side effects. [More]
Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers find new 'sliding scale' model to rule out blood clots in lungs

Researchers from Intermountain Medical Center in Salt Lake City have identified a new "sliding scale" model used to rule out potentially deadly blood clots in the lungs, known as pulmonary embolisms, that is more accurate than current diagnostic methods. [More]
MU researcher developing nano-scale molecules to image, treat different diseases

MU researcher developing nano-scale molecules to image, treat different diseases

Nanomedicine is the medical application of nanotechnology, or the use of microscopic structures to diagnose, image, treat and prevent disease. Current problems in nanomedicine include understanding and anticipating the potentially toxic impact these nanostructures have on the body and the environment once they're released. [More]
Genomic Health reports positive results from Oncotype DX clinical study in women with DCIS

Genomic Health reports positive results from Oncotype DX clinical study in women with DCIS

Genomic Health, Inc. today announced positive results from the second large clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). [More]
Study suggests that hospitals perform more partial nephrectomies after acquiring robots

Study suggests that hospitals perform more partial nephrectomies after acquiring robots

Hospitals with robotic surgical systems are more likely to perform "nephron-sparing" partial nephrectomy--a recommended alternative to removal of the entire kidney--in patients with kidney cancer, reports a study in the December issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. [More]
Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer. [More]
OncoTherapy Network discusses latest research on prostate cancer

OncoTherapy Network discusses latest research on prostate cancer

UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer. [More]
Cancer Council urges partners of men diagnosed with prostate cancer to reach out for support

Cancer Council urges partners of men diagnosed with prostate cancer to reach out for support

Cancer Council is calling on partners of men with prostate cancer to reach out for support, with research showing partners experience high levels of distress related to the diagnosis of their loved one. [More]
Report supports potential of focused ultrasound to treat certain OCD patients

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD). [More]
BAZ2A protein directly influences the aggressiveness of prostate cancer

BAZ2A protein directly influences the aggressiveness of prostate cancer

A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue. [More]
Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure. The cultures test for antibiotic-resistant E. coli, and the findings are used to direct the selection of antimicrobial prophylaxis used for the procedure, according to Rhode Island Hospital researchers. [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
ASTRO recognized with three 2014 MarCom Awards

ASTRO recognized with three 2014 MarCom Awards

The American Society for Radiation Oncology received three 2014 MarCom Awards. MarCom Awards were presented to ASTRO for the Summer 2014 issue of ASTROnews, the RO-ILS: Radiation Oncology Incident Learning SystemTM marketing campaign and the most recent edition of the Radiation Therapy for Prostate Cancer patient brochure. [More]
Endocrinologist examines benefits and harms of testosterone therapy

Endocrinologist examines benefits and harms of testosterone therapy

An article in the latest edition of Australian Prescriber looks at the prescribing of testosterone, often used for ‘male menopause’ symptoms such as reduced energy, poor concentration and increased body fat. Over the past decade there has been a steep rise in the amount of testosterone dispensed in Australia and globally. [More]
Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide. [More]
Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. [More]
Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA. [More]